This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Catzavelos, C. Articles by Slingerland, J. M. Search for Related Content PubMed PubMed Citation Articles by Catzavelos, C. Articles by Slingerland, J. M.

Reduced Expression of the Cell Cycle Inhibitor p27^Kip1 in Non-Small Cell Lung Carcinoma

A Prognostic Factor Independent of Ras¹

Departments of Laboratory Medicine and Pathology [M-S. T.] and Medical Oncology [F. S.], Ontario Cancer Institute/Princess Margaret Hospital and The Toronto Hospital, Toronto, Ontario M5G 2M9; Departments of Medical Biophysics [M-S. T., J. M. S., G. D.], Pathology [C. C.], and Cancer Research [J. M. S., N. B.], Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5; and Departments of Medical Oncology [J. M. S.] and Clinical Trials and Epidemiology [G. D.], Toronto-Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario M4N 3M5, Canada

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Levels of p27 have been found to have independent prognostic significance in a variety of tumors including breast, colon, prostate, ovary, and gastric carcinomas. We investigated p27 levels and determined rasmutational status in 136 non-small cell lung cancers. We found reduced levels of p27 in 86% of cases and showed a statistically significant inverse correlation between p27 levels and tumor grade. ras mutations were found exclusively in adenocarcinomas and showed no relationship to p27 levels. Clinical data on a subset of the patients studied indicated that all 16 patients who died of disease and 21 of 22 patients who relapsed had low p27 levels, whereas all patients with high p27 levels were alive at la st follow up. These findings suggest that alteration in p27 levels plays an important role in lung tumor progression and that p27 levels may have independent prognostic significance in non-small cell lung cancer.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Altered regulation of the cell cycle is a hallmark of human cancers (1) . The cell cycle is governed by cdks,³ the activity of which is regulated by binding of positive effectors, the cyclins (2 , 3) , by negative regulators, the cdk inhibitors (4 , 5) , and by phosphorylation and dephosphorylation events (6 , 7) . The cdks integrate mitogenic and growth inhibitory signals and coordinate cell cycle transitions (2 , 3) . Passage through G₁ into S phase is regulated by the activities of cyclin D-, cyclin E-, and cyclin A-associated kinases. B-type cdks regulate the G₂-M phases. Two families of cdk inhibitors have been identified (4 , 5) . INK4 family members p15, p16, p18, and p19 bind cyclin D-dependent cdks, specifically cdk4 and cdk6. KIP family members, including p21^Cip1, p27^Kip1, and p57^Kip2, bind and inhibit their target cyclin/cdks. The cdk inhibitors regulate entry into and progression through the cell cycle by modulating the activity of cdks in response to mitogenic and antimitogenic stimuli. The cyclins, cdks, and cdk inhibitors are frequently altered in cancer or disrupted secondarily by other oncogenic events (1) .

p27^Kip1 is a cdk inhibitor, which regulates progression from G₁ into S phase (4) . Regulation of this protein occurs primarily at the posttranslational level by proteasomal degradation (8, 9, 10) . p27^Kip1 binds and inhibits its target cdks in a stoichiometric manner; therefore, the availability of p27^Kip1 is critical in the regulation of cyclin/cdk activity. Although mutations in the p27^Kip1 gene are rare in human tumors (11, 12, 13, 14) , decreased p27^Kip1 protein levels are found in aggressive cancers of the breast (15, 16, 17) , colon (18) , prostate (19) , and gastric mucosa (20) , suggesting that its loss may both reflect and participate in the process of tumor progression. NSCLC represents 75% of all lung cancers. Its overall prognosis is poor, with a 5-year survival rate of 15%. Even for stage I, the survival rate after complete surgical resection is only 60–70%, and for stage II it falls to 40–50%. Patients whose resected lung tumor shows certain distinct genetic and biological features seem at even greater risk of relapse and death from this disease (21 , 22) . An important genetic/biological prognostic factor in ADCs is activation of the Ki-ras oncogene (23, 24, 25) . We have recently evaluated the prevalence of ras mutations, microvessel and vascular endothelial factor CVE of NSCLC. The present study was undertaken to assess p27^Kip1 levels in this cohort of NSCLC specimens to evaluate its potential use as a prognostic factor, and to assess the relationship between alteration in p27^Kip1 levels and ras mutations. We show that p27^Kip1 protein levels are frequently reduced in primary NSCLCs and provide evidence to suggest that loss of p27 may be an important indicator of poor prognosis in this group of patients.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Tissue Material.
Frozen tissues and formalin-fixed paraffin blocks of primary NSCLC and corresponding normal lung parenchyma were obtained from lobectomy or pneumonectomy specimens. These were sampled within 2 h after resection. The tissues were snap-frozen in liquid nitrogen and stored at -80°C until RNA extraction. Paraffin blocks were processed according to routine surgical pathological technique. A total of 136 NSCLC tumors were examined in this study; sixty-four were from specimens resected at the Montreal General Hospital, and 72 cases were obtained from the Canadian Lung Tumor Bank, established in association with the National Cancer Institute of Canada-Clinical Trial Group BR.10 protocol. Tumors were classified according to the WHO classification (26) and were staged according to the tumor-node-metastasis staging system adopted by the American Joint Committee on Cancer and the Union Internationale Contre le Cancer (27) . The entire study cohort included 92 ADCs, 26 SQCCs, and 18 LCUCs. Clinical follow-up data were available for 67 BR.10 patients who entered the study between July 1994 and January 1996. Their median follow-up was 25 months (range, 16 days-3.1 years).

Ras Mutation Analysis.
Genomic DNA was extracted from frozen normal lung and tumor tissues, as described previously (28) . The presence of mutations in Ha-ras, Ki-ras, and N-ras were identified using PCR, followed by hybridization with allele (mutant)-specific oligonucleotide probes (29) . The PCR amplification primers (amplimers) for exons 1 and 2 of Ki-ras, Ha-ras, and N-ras genes were purchased from Clontech Laboratories, Inc. (Palo Alto, CA).

The oligonucleotide probes for the wild type and mutant alleles of codons 12, 13, and 61 of Ha-ras, Ki-ras, and N-ras were those contained in the MUTA-LYZER Clontech kit. Each codon-specific kit contains a panel of either seven or eight individual oligonucleotide probes that correspond either to the wild type or to pertinent mutations of the indicated ras gene. End-labeling of the probe and dot-blotting were carried out as previously described (29) . Ras mutations were identified using a two-step screening procedure that allowed evaluation of all 57 potential mutations. Positive ras mutations were confirmed by sequencing, as described (29) .

Immunohistochemistry.
For each case, five micron sections were prepared from representative formalin-fixed and paraffin-embedded tumor tissue from the surgical pathology archival blocks. Expression of the p27^Kip1 protein was determined immunohistochemically. Paraffin sections of tumor blocks were deparaffinized with xylene, rehydrated, and microwaved in 10 mM citrate buffer (pH 6.0). Sections were blocked with 3% hydrogen peroxide in methanol, followed by normal horse serum (1:20 dilution) in 0.1 M PBS (pH 6.0), and then incubated overnight at 4°C with anti-p27^Kip1 monoclonal antibody (Transduction Laboratories, Lexington, KY) diluted 1:1000 (0.25 µg/ml) in PBS. Slides were then reacted with biotin-labeled antimouse immunoglobulin G and incubated with preformed avidin-biotin-peroxidase complex (Vector Laboratories, Burlingame, CA). Metal-enhanced diaminobenzidine substrate (Pierce Chemical Co., Rockford, IL) was then added in the presence of horseradish peroxidase. Sections were counterstained with hematoxylin, dehydrated, and mounted. Tumor histology, grade, and p27^Kip1 staining were scored independently by two pathologists (C. C. and M-S. T.). Between 15 and 20 high power fields of tumor were scored for the percentage of nuclei showing positive p27^Kip1 staining. The scoring system used was as in our previous studies (15) : 1 = 0–25%, 2 = 25–50%, 3 = 50–75%, and 4 = >75% positive nuclear staining.

Statistical Analysis.
Calculations were performed using SAS (release 6.12; SAS Institute Inc., Cary, NC). Associations between p27^kip1 and other tumor covariates were assessed with Spearman correlation coefficients. Survival curves were calculated by the Kaplan-Meier method (30) and compared with the logrank test (31) .

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Reduced p27^Kip1 Protein in NSCLC.
Strong nuclear p27^Kip1 staining was consistently seen in normal bronchial epithelial cells and in infiltrating lymphocytes, and these provided internal staining controls in most tumors. Similar patterns of p27^Kip1 staining were seen with a polyclonal anti- p27^Kip1 antibody, and the immunoreactivity was lost when the antibody was blocked with a control peptide. Of the 136 cases in the study, p27^Kip1 staining was technically not feasible in 3 cases, and these were excluded from further analysis. There was a consistent reduction in the nuclear p27^Kip1 staining in all of the histological subtypes (ADC, SQCC, and LCUC). Examples of p27^Kip1 staining in normal mucosa and tumor samples are shown in Fig. 1, A–C . Within the SQCCs, p27^Kip1 levels were lowest at the periphery of tumor nodules and often high at the center of tumor nodules adjacent to areas of necrosis (Fig. 1, D and E) .

View larger version (123K): [in this window] [in a new window] [Download PPT slide]   Fig. 1. p27Kip1 immunostaining in NSCLC. Paraffin-embedded tissues from lung carcinomas were immunostained for p27Kip1 and counterstained with hematoxylin, as described in "Materials and Methods." A, p27Kip1 staining in normal human bronchial epithelium. B, p27Kip1 stain in a moderately differentiated SQCC showing high levels of p27Kip1 staining (>50% nuclei positive). C, p27Kip1 stain in a poorly differentiated ADC showing low p27Kip1 (<50% nuclei positive). D and E, p27Kip1 staining is reduced at the periphery of a SQCC tumor nodule and increased at the center of the nodule adjacent to the region of tumor necrosis.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Our data yield several conclusions: (a) p27^Kip1 levels are frequently reduced in NSCLC; (b) loss of p27^Kip1 is correlated with increasing tumor grade; and (c) ras mutations arise independently of changes in p27^Kip1 levels.

We have shown that levels of the cell cycle inhibitor p27^Kip1 are frequently reduced in non-small cell carcinomas of lung compared with levels seen in normal human bronchial epithelium. Low p27^Kip1 levels (staining in <50% of tumor nuclei) were seen in 86% of tumors in the entire group (n = 133). Loss of the p27^Kip1 protein has been observed in other cancers, including breast, colon, prostate (15, 16, 17, 18, 19 , 32) , and ovary.⁴ This suggests that p27^Kip1 is important in the regulation of epithelial cell proliferation and that it is a common target for alteration in human tumors. As such, reduced levels of this protein may play an important role in tumor progression. The loss of p27^Kip1 may reflect changes in the proliferative fraction, although there is no clear correlation between decreased p27^Kip1 and tumor proliferation at present. In breast and colon cancers, low p27^Kip1 did not correlate with an increased percentage of S phase or with increased expression of the proliferation marker, MIB-1 (15, 16, 17, 18) . As a result, it could reflect changes in other properties such as cell-cell adhesion and increased metastatic potential (33, 34, 35, 36, 37) . Decreased p27^Kip1 levels can occur in human tumors in the presence of abundant p27^Kip1 mRNA expression (15 , 17 , 18 , 32) , consistent with recent studies that have demonstrated that reduced p27^Kip1 levels are posttranslationally regulated, at least in part, by proteasomal degradation (8, 9, 10 , 18 , 32) . The molecular factors responsible for reduced p27^Kip1 levels in tumor progression are not clear at present.

In this study, p27^Kip1 levels showed a statistically significant inverse correlation with tumor grade. High levels of p27^Kip1 (staining in >50% of tumor nuclei) were seen in one-third of well differentiated (low grade) tumors, but only in 8% of the poorly differentiated group. A similar inverse correlation between p27^Kip1 and tumor grade has been observed in breast, prostate, and colon carcinomas (15, 16, 17, 18, 19) . This may in part be explained by recent observations that p27^Kip1 plays an important part in normal differentiation (38, 39, 40) , and that p27^Kip1 levels are regulated in part by E-cadherin (41) , a key molecule involved in epithelial cell-cell adhesion, which is frequently reduced during tumor progression.

The association between low p27^Kip1 and poor tumor grade suggests that low p27^Kip1 may have prognostic potential in NSCLC. In particular, high p27^Kip1 may define a more favorable prognostic group. Esposito et al. (32) recently reported that low p27^Kip1 was an indicator of poor prognosis in a cohort of 108 patients with NSCLC on univariate analysis. Yatabe et al. (42) reported similar findings. We did not have access to follow-up data on the cohort of patients from the Montreal General Hospital. We did, however, have follow-up data on 67 patients from the BR.10 study in which patients with resectable NSCLC were randomized to receive or to not receive adjuvant chemotherapy. The median duration of follow-up in this study, which began in July 1994, was 25 months. The immaturity of follow-up in this smaller cohort of patients precluded significant analysis of p27^Kip1 on disease outcome. However, it is worth noting that all of the 16 individuals who died during the study period had tumors with low p27^Kip1. Low p27 levels were also observed in 21 of the 22 cases that suffered a relapse during the follow-up period, and all but one patient with high tumor p27 levels were alive and relapse-free at last follow-up. These observations suggest that p27^Kip1 levels may be an important indicator of prognosis in NSCLC and indicate the need for a larger study with longer follow up to test this hypothesis.

Although a number of chemotherapeutic agents have shown activity in NSCLC, both response rates and duration have been disappointing. The distribution of p27^Kip1 staining in the SQCC tumor may shed light on the chemoresistance of this cancer. Recent studies of tumor spheroids grown in three-dimensional culture have shown that tightly adhesive spheroids have both reduced proliferative rates and reduced responsiveness to alkylating chemotherapy (33) . It is possible, using antisense oligonucleotides, to decrease p27^Kip1 levels (33) and to increase the proliferative fraction (percentage of cells in S phase) and reduce cell-cell adhesion. Antisense p27-treated spheroids are, thus, converted from tight aggregates to loose aggregates that are more responsive to chemotherapeutic agents. In the present in vivo study of SQCC lung tumors, as in our previous studies of cultured spheroids, we observed reduced p27^Kip1 immunostaining at the periphery with higher levels at the center (Fig. 1, D and E) . The increased p27^Kip1 in cells adjacent to necrotic tumor in vivo may reflect the cytostasis induced by hypoxia and low pH. Nonproliferating cancer cells are typically resistant to cytotoxic agents that rely on DNA synthesis and/or tumor proliferation for activity (43) . The population of cells expressing high p27^Kip1 protein in SQCC may identify a chemoresistant fraction that is recruited into cycle and repopulates after the more proliferatively active portion of the tumor is killed by cytotoxic agents. New drugs that recruit this population into cycle before treatment may improve the efficacy of chemotherapy; alternatively, drugs that prevent reentry of such cells into the cell cycle (i.e., mechanisms to maintain dormancy by manipulating p27^Kip1 levels) are both potential avenues for novel treatment strategies in NSCLC.

Finally, we have observed that ras mutations and loss of p27^Kip1 seem to occur independently in ADC. Ras mutations occur almost exclusively in ADC and, by an overwhelming majority (>90%), involve codon 12 of the Ki-ras gene (29) . Although recent reports link ras activation with changes in p27^Kip1 regulation (44, 45, 46) , the two show no association in ADC and, thus, have the potential to contribute independently to patient outcome. The fact that there was no particular influence of tumor type on p27^Kip1 levels is consistent with the observation that p27^Kip1 levels and ras mutations are independent, because ras mutations are largely confined to ADC (23 , 29 , 47 , 48) .

In summary, we have shown that p27^Kip1 levels are reduced in the majority of cases of NSCLC and that loss of p27 is statistically correlated with increased tumor size and with reduced tumor differentiation or high tumor grade. We also present evidence to suggest that p27^Kip1 levels may be an important prognostic factor in NSCLC, which indicates the need for larger studies with longer follow-up to assess this question.

	ACKNOWLEDGMENTS

 
We thank M. Viscardi for assistance in preparation of the manuscript. The establishment of the Canadian Lung Tumor Bank is partially supported by the Glaxo-Wellcome Pharmaceutical Company.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by the Canadian Cancer Society through Grant 4493 from the National Cancer Institute of Canada and by grants from the Canadian Breast Cancer Research Initiative (to J. M. S and C. C.). J. M. S. (Clinician Investigator) and G. D. are supported by Cancer Care Ontario.

² To whom requests for reprints should be addressed, at Cancer Biology Research, S-Wing Room 238, Sunnybrook Health Science Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada. Phone: (416) 480-6100, ext. 3494; Fax: (416) 480-5703; E-mail: joyce.slingerland{at}utoronto.ca

³ The abbreviations used are: cdk, cyclin-dependent kinase; NSCLC, non-small cell lung carcinoma; KIP, 2kinase inhibitor protein; ADC, adenocarcinoma; SQCC, squamous cell carcinoma; LCUC, large cell undifferentiated carcinoma; INK4, inhibitor of cdk4.

⁴ J. Slingerland and P. Shaw, unpublished data.

Received 9/ 1/98. Accepted 12/ 1/98.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Hunter T., Pines J. Cyclins, and cancer II. Cyclin D and cdk inhibitors come of age. Cell, 79: 573-582, 1994.[Medline]
2. Morgan D. O. Principles of cdk regulation. Nature (Lond.), 374: 131-134, 1995.[Medline]
3. Sherr C. J. G1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.[Medline]
4. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.[Free Full Text]
5. Reed S. I., Bailly E., Dulic V., Hengst L., Resnitzky D., Slingerland J. G1 control in mammalian cells. J. Cell Science, 18 (Suppl.): 69-73, 1994.
6. Norbury C., Nurse P. Animal cell cycles and their control. Annu. Rev. Biochem., 61: 441-470, 1992.[Medline]
7. Solomon M. J. Activation of the various cyclin/cdc2 proteins. Curr. Opin. Cell Biol., 5: 180-186, 1993.[Medline]
8. Pagano M., Tam S. W., Theodoras A. M., Beer-Romero P., Del Sal G., Chau V., Yew P. R., Draetta G. F., Rolfe M. Role of ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.[Abstract/Free Full Text]
9. Vlach J., Hennecke S., Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27^Kip1. EMBO J., 16: 5334-5344, 1997.[Medline]
10. Sheaff R. J., Groudine M., Gordon M., Roberts J. M., Clurman B. E. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev., 11: 1464-1478, 1997.[Abstract/Free Full Text]
11. Ponce-Castaneda M. V., Lee M-H., Latres E., Polyak K., Lacombe L., Montgomery K., Mathew S., Krauter K., Sheinfeld J., Massague J., Cordon-Cardo C. p27^Kip1: chromosomal mapping to 12p12–12p13.1 and absence of mutations in human tumors. Cancer Res., 55: 1211-1214, 1995.[Abstract/Free Full Text]
12. Pietenpol J. A., Bohlander S. K., Sato Y., Papadopoulos N., Liu B., Friedman C., Trask B. J., Roberts J. M., Kinzler K. W., Rowley J. D., Vogelstein B. Assignment of human p27^Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res., 55: 1206-1210, 1995.[Abstract/Free Full Text]
13. Ferrando A., Balbin M., Pendas A. M., Vizoso F., Velasco G., Lopez-Otin C. Mutational analysis of the human cyclin-dependent kinase inhibitor p27Kip1 in primary breast carcinomas. Hum. Genet., 97: 91-94, 1996.[Medline]
14. Kawamata N., Morosetti R., Miller C. W., Park D., Spirin K. S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilczynski S., Young Y. L., Bartram C. R., Koeffler H. P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27^Kip1 in human malignancies. Cancer Res., 55: 2266-2269, 1995.[Abstract/Free Full Text]
15. Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard K. I., Slingerland J. M. Decreased levels of the cell cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.[Medline]
16. Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat. Med., 3: 222-225, 1997.[Medline]
17. Tan P., Cady B., Wanner M., Worland P., Cukor B., Magi-Galluzzi C., Lavin P., Draetta G., Pagano M., Loda M. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a, b) invasive breast carcinomas. Cancer Res., 57: 1259-1263, 1997.[Abstract/Free Full Text]
18. Loda M., Cukor B., Tam S. W., Lavin P., Fiorentino M., Draetta G. F., Jessup J. M., Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med., 3: 231-234, 1997.[Medline]
19. Tsihlias J., Kapusta L. R., DeBoer G., Morava-Protzner I., Zbieranowski I., Bhattacharya N., Catzavelos G. C., Klotz L. H., Slingerland J. M. Loss of cyclin dependent kinase inhibitor p27^Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res., 58: 542-548, 1998.[Abstract/Free Full Text]
20. Mori M., Mimori K., Shiraishi T., Tanaka S., Ueo H., Sugimachi K., Akiyoshi T. p27 expression and gastric carcinoma. Nat. Med., 3: 593-, 1997.[Medline]
21. Mountain C. F. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest, 108: 246-254, 1995.[Free Full Text]
22. Moore J. D. F., Lee J. S. Staging and prognostic factors: non-small cell lung cancer Pass H. I. Mitchell J. B. Johnson D. H. Turrisi A. T. eds. . Lung Cancer: Principles and Practice, : 481-494, Lippincott-Raven Publishers Philadelphia 1996.
23. Rodenhuis S., Slebos R. J. C. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res., 52: 2665s-2669s, 1992.[Abstract/Free Full Text]
24. Sugio K., Ishida T., Yokoyama H., Inoue T., Sugimachi K., Saszuki T. ras gene mutation as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res., 52: 2903-2906, 1992.[Abstract/Free Full Text]
25. Mitsudomi T., Sterinberg S. M., Oie H. K., Mulshine J. L., Phelps R., Vialleet J., Pass H., Minna J. D., Gazdar A. F. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res., 51: 4999-5002, 1991.[Abstract/Free Full Text]
26. WHO Histological typing of lung tumors. Am. J. Clin. Pathol., 77: 123-136, 1982.[Medline]
27. Mountain C. F. A new international staging system for lung cancer. Chest, 89: 225s-233s, 1986.
28. Liu C., Tsao M. S. Proto-oncogene and growth factor/receptor expression in the establishment of primary human non-small cell lunch carcinoma cell lines. Am. J. Pathol., 142: 413-423, 1993.[Abstract]
29. Tsao M., Liu N., Nicklee T., Shepherd F., Viallet J. Angiogenesis correlates with vascular endothelial growth factor expression but not with Ki-ras oncogene activation in non-small cell lung carcinoma. Oncogene, 3: 1807-1814, 1997.
30. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. Am. Stat. Assoc. J., 53: 457-481, 1958.
31. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer, 35: 1-39, 1977.[Medline]
32. Esposito V., Baldi A., De Luca A., Groger A. M., Loda M., Giordano G. G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res., 57: 3381-3385, 1997.[Abstract/Free Full Text]
33. St. Croix B., Florenes V., Rak A., Flanagan J. W., Bhattacharya N., Slingerland J. M., Kerbel R. S. Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.[Medline]
34. Radeva G., Petrocelli T., Behrend E., Leung-Hagesteijn C., Filmus J., Slingerland J., Dedhar S. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J. Biol. Chem., 272: 13937-13944, 1997.[Abstract/Free Full Text]
35. Zhu X., Ohtsubo M., Bohmer R. M., Roberts J. M., Assoian R. K. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol., 133: 391-403, 1996.[Abstract/Free Full Text]
36. Fang F. G., Watanabe N., Hunter T., Ruoslahti E. Dependence of cyclin E-cdk2 kinase activity on cell anchorage. Science (Washington DC), 271: 499-502, 1996.[Abstract]
37. Assoian R. K. Anchorage-dependent cell cycle progression. J. Cell Biol., 136: 1-3, 1997.[Free Full Text]
38. Fero M. L., Rivkin M., Tasch M., Porter P., Carow C. E., Polyak K., Firpo E., Tsai L., Broudy V., Perlmutter R. M., Kaushansky K., Roberts J. M. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27Kip1-deficient mice. Cell, 85: 733-744, 1996.[Medline]
39. Kiyokawa H., Kineman R. D., Manova-Todorova K. O., Soares V. C., Hoffman E. S., Ono M., Khanam D., Hayday A. C., Frohman L. A., Koff A. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell, 85: 721-732, 1996.[Medline]
40. Nakayama K., Ishida N., Shirane M., Inomata A., Inoue T., Shishido N., Horii I., Loh D. Y., Nakayama K. Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell, 85: 707-720, 1996.[Medline]
41. St. Croix B., Sheehan C., Rak J., Florenes V. A., Slingerland J., Kerbel R. S. E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27^Kip1. J. Cell Biol., 142: 557-571, 1998.[Abstract/Free Full Text]
42. Yatabe Y., Masuda A., Nakamura S., Kuroishi T., Osada H., Takahashi T., Mitsudomi T. p27^Kip1 in human lung cancers: differential changes in small cell and non-small cell carcinomas. Cancer Res., 58: 1042-1047, 1998.[Abstract/Free Full Text]
43. Slingerland J. M., Tannock I. Control of cell proliferation and cell death Tannock I. Hill R. P. eds. . Basic Science of Oncology, : McGraw-Hill 1997.
44. Kawada M., Yamagoe S., Murakami Y., Suzuki K., Mizuno S., Uehara Y. Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene, 15: 629-637, 1997.[Medline]
45. Takuwa N., Takuwa Y. Ras activity late in G₁ phase required for p27kip1 down-regulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts. Mol. Cell. Biol., 17: 5348-5358, 1997.[Abstract]
46. Aktas H., Cai H., Cooper G. M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the cdk inhibitor p27^Kip1. Mol. Cell. Biol., 17: 3850-3857, 1997.[Abstract]
47. Westra W. H., Baas I. O., Hruban R. H., Askin F. B., Wilson K., Offerhaus G. J., Slebos R. J. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res., 56: 2224-2228, 1996.[Abstract/Free Full Text]
48. Keohavong P., DeMichele M. A. A., Melacrinos A. C., Landreneau R. J., Weyant R. J., Siegfried J. M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin. Cancer Res., 2: 411-418, 1996.[Abstract/Free Full Text]

This article has been cited by other articles:

				Y. Liu, S. A. Perdreau, P. Chatterjee, L. Wang, S.-F. Kuan, and A. Duensing Imatinib Mesylate Induces Quiescence in Gastrointestinal Stromal Tumor Cells through the CDH1-SKP2-p27Kip1 Signaling Axis Cancer Res., November 1, 2008; 68(21): 9015 - 9023. [Abstract] [Full Text] [PDF]

				C-Q Zhu, W Shih, C-H Ling, and M-S Tsao Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J. Clin. Pathol., August 1, 2006; 59(8): 790 - 800. [Abstract] [Full Text] [PDF]

				H. Sonoda, H. Inoue, K. Ogawa, T. Utsunomiya, T.-a. Masuda, and M. Mori Significance of Skp2 Expression in Primary Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1215 - 1220. [Abstract] [Full Text] [PDF]

				C. A. Martey, S. J. Pollock, C. K. Turner, K. M. A. O'Reilly, C. J. Baglole, R. P. Phipps, and P. J. Sime Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer Am J Physiol Lung Cell Mol Physiol, November 1, 2004; 287(5): L981 - L991. [Abstract] [Full Text] [PDF]

				A. Osoegawa, I. Yoshino, S. Tanaka, K. Sugio, T. Kameyama, M. Yamaguchi, and Y. Maehara Regulation of p27 by S-Phase Kinase-Associated Protein 2 Is Associated With Aggressiveness in Non-Small-Cell Lung Cancer J. Clin. Oncol., October 15, 2004; 22(20): 4165 - 4173. [Abstract] [Full Text] [PDF]

				C. Q. Zhu, F. H. Blackhall, M. Pintilie, P. Iyengar, N. Liu, J. Ho, T. Chomiak, D. Lau, T. Winton, F. A. Shepherd, et al. Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker Clin. Cancer Res., March 15, 2004; 10(6): 1984 - 1991. [Abstract] [Full Text] [PDF]

				D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]

				Z. Wang and M. J. Garabedian Modulation of Glucocorticoid Receptor Transcriptional Activation, Phosphorylation, and Growth Inhibition by p27Kip1 J. Biol. Chem., December 19, 2003; 278(51): 50897 - 50901. [Abstract] [Full Text] [PDF]

				S. J. Moeller, E. D. Head, and R. J. Sheaff p27Kip1 Inhibition of GRB2-SOS Formation Can Regulate Ras Activation Mol. Cell. Biol., June 1, 2003; 23(11): 3735 - 3752. [Abstract] [Full Text] [PDF]

				Y.-C. Huang, L.-Y. Chuang, and W.-C. Hung Mechanisms Underlying Nonsteroidal Anti-Inflammatory Drug-Induced p27Kip1 Expression Mol. Pharmacol., December 1, 2002; 62(6): 1515 - 1521. [Abstract] [Full Text] [PDF]

				G. Yang, G. Ayala, A. D. Marzo, W. Tian, A. Frolov, T. M. Wheeler, T. C. Thompson, and J. W. Harper Elevated Skp2 Protein Expression in Human Prostate Cancer: Association with Loss of the Cyclin-dependent Kinase Inhibitor p27 and PTEN and with Reduced Recurrence-free Survival Clin. Cancer Res., November 1, 2002; 8(11): 3419 - 3426. [Abstract] [Full Text] [PDF]

				W. Kammouni, G. Ramakrishna, G. Sithanandam, G. T. Smith, L. W. Fornwald, A. Masuda, T. Takahashi, and L. M. Anderson Increased K-Ras Protein and Activity in Mouse and Human Lung Epithelial Cells at Confluence Cell Growth Differ., September 1, 2002; 13(9): 441 - 448. [Abstract] [Full Text] [PDF]

				F. McGregor, A. Muntoni, J. Fleming, J. Brown, D. H. Felix, D. G. MacDonald, E. K. Parkinson, and P. R. Harrison Molecular Changes Associated with Oral Dysplasia Progression and Acquisition of Immortality: Potential for Its Reversal by 5-Azacytidine Cancer Res., August 15, 2002; 62(16): 4757 - 4766. [Abstract] [Full Text] [PDF]

				R. M. Bremnes, R. Veve, E. Gabrielson, F. R. Hirsch, A. Baron, L. Bemis, R. M. Gemmill, H. A. Drabkin, and W. A. Franklin High-Throughput Tissue Microarray Analysis Used to Evaluate Biology and Prognostic Significance of the E-Cadherin Pathway in Non-Small-Cell Lung Cancer J. Clin. Oncol., May 15, 2002; 20(10): 2417 - 2428. [Abstract] [Full Text] [PDF]

				Y. A. Elsayed and E. A. Sausville Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins Oncologist, December 1, 2001; 6(6): 517 - 537. [Abstract] [Full Text] [PDF]

				W.-C. Hung, H.-C. Chang, M.-R. Pan, T.-H. Lee, and L.-Y. Chuang Induction of p27KIP1 as a Mechanism Underlying NS398-Induced Growth Inhibition in Human Lung Cancer Cells Mol. Pharmacol., April 13, 2001; 58(6): 1398 - 1403. [Abstract] [Full Text]

				M. Gstaiger, R. Jordan, M. Lim, C. Catzavelos, J. Mestan, J. Slingerland, and W. Krek Skp2 is oncogenic and overexpressed in human cancers PNAS, April 12, 2001; (2001) 81474898. [Abstract] [Full Text]

				F. Hommura, H. Dosaka-Akita, T. Mishina, M. Nishi, T. Kojima, H. Hiroumi, S. Ogura, M. Shimizu, H. Katoh, and Y. Kawakami Prognostic Significance of p27KIP1 Protein and Ki-67 Growth Fraction in Non-small Cell Lung Cancers Clin. Cancer Res., October 1, 2000; 6(10): 4073 - 4081. [Abstract] [Full Text]

				A. M. Oliveira, A. G. Nascimento, S. H. Okuno, and R. V. Lloyd p27kip1 Protein Expression Correlates With Survival in Myxoid and Round-Cell Liposarcoma J. Clin. Oncol., August 15, 2000; 18(15): 2888 - 2893. [Abstract] [Full Text] [PDF]

				A. M. Mirza, A. D. Kohn, R. A. Roth, and M. McMahon Oncogenic Transformation of Cells by a Conditionally Active Form of the Protein Kinase Akt/PKB Cell Growth Differ., June 1, 2000; 11(6): 279 - 292. [Abstract] [Full Text]

				H. Nagase, J.-H. Mao, and A. Balmain A subset of skin tumor modifier loci determines survival time of tumor-bearing mice PNAS, December 21, 1999; 96(26): 15032 - 15037. [Abstract] [Full Text] [PDF]

				M. Gstaiger, R. Jordan, M. Lim, C. Catzavelos, J. Mestan, J. Slingerland, and W. Krek Skp2 is oncogenic and overexpressed in human cancers PNAS, April 24, 2001; 98(9): 5043 - 5048. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Catzavelos, C. Articles by Slingerland, J. M. Search for Related Content PubMed PubMed Citation Articles by Catzavelos, C. Articles by Slingerland, J. M.